Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Business Decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| MAP Health Management LLC | UNKNOWN |
Not provided
Not provided
Not provided
The purpose of this study is to show the effectiveness of Soberlink's remote alcohol monitoring system integrated with MAP's patient engagement platform (EHR) to monitor a sample size of at-risk alcohol use disorder (AUD) population. Ultimately, this data is leveraged to improve clinical outcomes and manage financial risk through facilitating early interventions and other means of mitigating recidivism and costly treatment episodes from AUD population.
The study will include 30 Clients with a primary or secondary diagnosis of alcohol use disorder (AUD) and are enrolled in MAP's System where dedicated Case Managers are monitoring the Client's relapse risk levels. Soberlink's remote alcohol system will provide data to inform the Case Manager if the Client has relapsed or is at risk of relapsing through the use of testing data compiled by the Soberlink System. Integrating Soberlink results into MAP's EMR will allow Case Manager to make better clinical decisions and reduce costs by mitigating the chances recidivism through early intervention. Clients will use the Soberlink Device for a period of 90 days.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Primary diagnosis alcohol use disorder (AUD) | Primary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System |
| |
| Secondary diagnosis alcohol use disorder (AUD) | Secondary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Soberlink Cellular Device | Device | Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses. |
| Measure | Description | Time Frame |
|---|---|---|
| Recidivism | Determination of client relapse or risk of relapsing through the use of testing data compiled by the Soberlink Cellular Device | 90 days duration of subject participation |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
30 adult male/female clients with a primary or secondary diagnosis of alcohol use disorder (AUD) and are enrolled in MAP's System where dedicated Case Managers are monitoring the Client's relapse risk levels.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shannon Hanrahan, PhD | Shannon Hanrahan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MAP Health Management LLC | Austin | Texas | 78746 | United States |
Not provided
| Label | URL |
|---|---|
| CDC Ambulatory Health Care Data | View source |
| American Cancer Society - Alcohol Use and Cancer | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
|
|